Display options
Cite
Zustovich F, Lombardi G, Pastorelli D, et al. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol. 2011;3:69-82doi: 10.2147/OAJU.S7230.
Zustovich, F., Lombardi, G., Pastorelli, D., Farina, P., Bianco, M. D., De Zorzi, L., Palma, M. D., Nicoletto, O., & Zagonel, V. (2011). Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open access journal of urology, 369-82. https://doi.org/10.2147/OAJU.S7230
Zustovich, Fable, et al. "Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma." Open access journal of urology vol. 3 (2011): 69-82. doi: https://doi.org/10.2147/OAJU.S7230
Zustovich F, Lombardi G, Pastorelli D, Farina P, Bianco MD, De Zorzi L, Palma MD, Nicoletto O, Zagonel V. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230. PMID: 24198638; PMCID: PMC3818940.
Copy Download .nbib Format: NLM
Share it on

Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230.

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Open access journal of urology

Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Massimo Dal Bianco, Luca De Zorzi, Maurizia Dalla Palma, Ornella Nicoletto, Vittorina Zagonel

Affiliations

  1. Oncologia Medica 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy.

PMID: 24198638 PMCID: PMC3818940 DOI: 10.2147/OAJU.S7230

Abstract

Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

Keywords: angiogenesis; pharmacokinetics; sorafenib

References

  1. J Clin Oncol. 2010 Feb 20;28(6):1061-8 - PubMed
  2. J Clin Oncol. 2007 May 10;25(14):1824-31 - PubMed
  3. J Clin Oncol. 2009 Mar 10;27(8):1280-9 - PubMed
  4. Science. 2003 Jul 4;301(5629):94-6 - PubMed
  5. J Clin Oncol. 2008 Oct 1;26(28):4572-8 - PubMed
  6. Ann Oncol. 2008 Nov;19(11):1955-61 - PubMed
  7. Acta Oncol. 2009;48(7):964-70 - PubMed
  8. Expert Rev Anticancer Ther. 2008 Jan;8(1):63-73 - PubMed
  9. Clin Cancer Res. 2005 Aug 1;11(15):5472-80 - PubMed
  10. Semin Oncol. 2000 Apr;27(2):177-86 - PubMed
  11. Anticancer Drugs. 2009 Jul;20(6):409-15 - PubMed
  12. Nat Rev Drug Discov. 2006 Oct;5(10):835-44 - PubMed
  13. Eur J Cancer. 2009 Mar;45(5):765-73 - PubMed
  14. J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63 - PubMed
  15. Cancer. 2010 Jan 1;116(1):57-65 - PubMed
  16. Cancer Chemother Pharmacol. 2006 May;57(5):685-92 - PubMed
  17. Ann Oncol. 2011 Aug;22(8):1812-23 - PubMed
  18. J Clin Oncol. 2009 Apr 10;27(11):1800-5 - PubMed
  19. Eur J Cancer. 2006 Oct;42(15):2472-9 - PubMed
  20. Cancer Sci. 2008 Jan;99(1):159-65 - PubMed
  21. Eur J Cancer. 2010 Sep;46(13):2432-40 - PubMed
  22. Oncologist. 2005 Mar;10(3):198-204 - PubMed
  23. J Clin Oncol. 2007 Aug 1;25(22):3296-301 - PubMed
  24. J Clin Oncol. 2010 May 1;28(13):2144-50 - PubMed
  25. Cancer. 2010 Dec 1;116(23):5383-90 - PubMed
  26. J Clin Oncol. 2009 Jan 10;27(2):235-41 - PubMed
  27. Cancer. 2009 Jan 1;115(1):61-7 - PubMed
  28. Clin Cancer Res. 2009 Dec 15;15(24):7749 - PubMed
  29. J Clin Oncol. 2004 Dec 15;22(24):4991-5004 - PubMed
  30. Oncology. 2008;74(3-4):245-6 - PubMed
  31. Curr Opin Oncol. 2001 May;13(3):199-203 - PubMed
  32. J Clin Oncol. 2008 Jan 1;26(1):127-31 - PubMed
  33. Expert Rev Anticancer Ther. 2010 Jun;10(6):825-35 - PubMed
  34. Semin Urol Oncol. 1996 Nov;14(4):237-43 - PubMed
  35. J Urol. 2008 Jan;179(1):81-6; discussion 86 - PubMed
  36. J Urol. 2009 Jul;182(1):29-34; discussion 34 - PubMed
  37. BJU Int. 2011 Apr;107(8):1190-9 - PubMed
  38. Clin Genitourin Cancer. 2009 Aug;7(2):E10-5 - PubMed
  39. Clin Genitourin Cancer. 2008 Mar;6(1):7-8 - PubMed
  40. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  41. Cancer. 2010 Sep 15;116(18):4256-65 - PubMed
  42. J Clin Oncol. 2006 Mar 20;24(9):1363-9 - PubMed
  43. N Engl J Med. 2007 Jan 11;356(2):115-24 - PubMed
  44. Drugs. 2009;69(2):223-40 - PubMed
  45. Urology. 2010 Aug;76(2):430-4 - PubMed
  46. Med Oncol. 2012 Jun;29(2):750-4 - PubMed
  47. Am J Clin Oncol. 2007 Jun;30(3):220-7 - PubMed
  48. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S79-84 - PubMed
  49. J Urol. 2001 Nov;166(5):1611-23 - PubMed
  50. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425 - PubMed
  51. J Clin Oncol. 2006 Sep 10;24(26):4293-300 - PubMed
  52. Curr Treat Options Oncol. 2003 Oct;4(5):363-72 - PubMed
  53. Br J Cancer. 2008 Nov 18;99(10):1579-85 - PubMed
  54. Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74 - PubMed
  55. Cancer Chemother Pharmacol. 2011 Apr;67(4):751-64 - PubMed
  56. J Clin Oncol. 2006 Jun 1;24(16):2505-12 - PubMed
  57. Cancer. 2010 Mar 1;116(5):1272-80 - PubMed
  58. Lancet. 2008 Aug 9;372(9637):449-56 - PubMed
  59. Br J Cancer. 2005 May 23;92(10):1855-61 - PubMed
  60. J Clin Oncol. 2010 May 1;28(13):2137-43 - PubMed
  61. N Engl J Med. 2007 May 31;356(22):2271-81 - PubMed
  62. Cancer. 2006 Nov 15;107(10):2375-83 - PubMed
  63. Nat Med. 2006 Jan;12(1):122-7 - PubMed
  64. N Engl J Med. 2007 Jan 11;356(2):125-34 - PubMed
  65. Semin Oncol. 2000 Apr;27(2):115-23 - PubMed
  66. Cancer. 1997 Sep 1;80(5):987-9 - PubMed
  67. Science. 2002 Jun 28;296(5577):2404-7 - PubMed
  68. Oncologist. 2008 Sep;13(9):1001-11 - PubMed
  69. Lancet. 1998 Nov 21;352(9141):1691-6 - PubMed
  70. J Clin Oncol. 2009 Jul 10;27(20):3312-8 - PubMed
  71. Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1 - PubMed

Publication Types